- Section 1 - About the Company
- AbbVie Inc - Key Facts
- AbbVie Inc - Key Employees
- AbbVie Inc - Key Employee Biographies
- AbbVie Inc - Major Products and Services
- AbbVie Inc - History
- AbbVie Inc - Company Statement
- AbbVie Inc - Locations And Subsidiaries
- Head Office
- Other Locations & Subsidiaries
- Section 2 – Company Analysis
- Company Overview
- AbbVie Inc - Business Description
- Product Category: Aesthetics
- Performance
- Product Category: Eye Care
- Performance
- Product Category: Immunology
- Performance
- Product Category: Neuroscience
- Performance
- Product Category: Oncology
- Performance
- Product Category: Other Key Products
- Performance
- Geographical Segment: International
- Performance
- Geographical Segment: United States
- Performance
- R&D Overview
- AbbVie Inc - Corporate Strategy
- AbbVie Inc - SWOT Analysis
- SWOT Analysis - Overview
- AbbVie Inc - Strengths
- AbbVie Inc - Weaknesses
- AbbVie Inc - Opportunities
- AbbVie Inc - Threats
- AbbVie Inc - Key Competitors
- Section 3 – Company Financial Ratios
- Financial Ratios - Capital Market Ratios
- Financial Ratios - Annual Ratios
- Performance Chart
- Financial Performance
- Financial Ratios - Interim Ratios
- Financial Ratios - Ratio Charts
- Section 4 – Company’s Lifesciences Financial Deals and Alliances
- AbbVie Inc, Pharmaceuticals & Healthcare, Deals By Year, 2018 to YTD 2024
- AbbVie Inc, Pharmaceuticals & Healthcare, Deals By Type, 2018 to YTD 2024
- AbbVie Inc, Recent Deals Summary
- Section 5 – Company’s Recent Developments
- Oct 30, 2024: AbbVie Announces Q3 2024 Results
- Oct 29, 2024: AbbVie signs agreement to acquire Aliada for $1.4bn
- Oct 29, 2024: Skinspirit Joins Allergan Aesthetics in Supporting Girls And Empowering the New Generation of Women in Stem
- Oct 18, 2024: BOTOX Cosmetic (onabotulinumtoxinA) Receives FDA Approval for Moderate to Severe Vertical Bands Connecting the Jaw and Neck (Platysma Bands)
- Oct 04, 2024: FDA Approves 16 New Cancer Treatments as Global Cancer Rates Skyrocket
- Oct 03, 2024: Alembic Pharmaceuticals Announces USFDA Final Approval for Alcaftadine Ophthalmic Solution, 0.25% (OTC).
- Oct 01, 2024: AbbVie to Host Third-Quarter 2024 Earnings Conference Call
- Sep 26, 2024: AbbVie and SpinUp Foster Canadian Life Sciences Innovation with the Launch of the AbbVie Biotech Innovators Award
- Sep 04, 2024: The AbbVie Foundation and Matter Launch the AbbVie Foundation Health Equity Accelerator
- Aug 02, 2024: AbbVie acquires Cerevel Therapeutics for $8.7bn
- Section 6 – Appendix
- Methodology
- Ratio Definitions
- About GlobalData
- Contact Us
- Disclaimer
- List of Tables
- AbbVie Inc, Key Facts
- AbbVie Inc, Key Employees
- AbbVie Inc, Key Employee Biographies
- AbbVie Inc, Major Products and Services
- AbbVie Inc, History
- AbbVie Inc, Subsidiaries
- AbbVie Inc, Key Competitors
- AbbVie Inc, Ratios based on current share price
- AbbVie Inc, Annual Ratios
- AbbVie Inc, Annual Ratios (Cont...1)
- AbbVie Inc, Annual Ratios (Cont...2)
- AbbVie Inc, Interim Ratios
- AbbVie Inc, Pharmaceuticals & Healthcare, Deals By Year, 2018 to YTD 2024
- AbbVie Inc, Pharmaceuticals & Healthcare, Deals By Type, 2018 to YTD 2024
- AbbVie Inc, Recent Deals Summary
- Currency Codes
- Capital Market Ratios
- Equity Ratios
- Profitability Ratios
- Cost Ratios
- Liquidity Ratios
- Leverage Ratios
- Efficiency Ratios
- List of Figures
- AbbVie Inc, Performance Chart (2019 - 2023)
- AbbVie Inc, Ratio Charts
- AbbVie Inc, Pharmaceuticals & Healthcare, Deals By Year, 2018 to YTD 2024
- AbbVie Inc, Pharmaceuticals & Healthcare, Deals by Type, 2018 to YTD 2024
Research Assistance
Download our eBook: How to Succeed Using Market Research
Learn how to effectively navigate the market research process to help guide your organization on the journey to success.
Download eBook